Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Expedia Stock: Soars to Record High on Stellar Earnings

Robert Sasse by Robert Sasse
August 9, 2025
in Stocks
0
Expedia Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Expedia’s shares surged 13.5% to a 52-week high of $212.06 on Friday, capping a 59.75% annual gain, fueled by stronger-than-expected Q2 results. The travel giant reported earnings of $4.24 per share, surpassing forecasts of $3.96, while revenue hit $3.79 billion against estimates of $3.7 billion. Key growth drivers included a 17% jump in B2B bookings and a 19% rise in advertising revenue, underscoring its robust international presence. Adjusted EBITDA margins expanded by 190 basis points to 24%, reflecting improved profitability.

Analysts Rally Behind Upgraded Targets

Wall Street responded with bullish price-target hikes, including raises to $218 (DA Davidson) and $240 (BofA). Efficiency gains—from job cuts and AI adoption—slashed overhead costs to 16.8% of revenue. While U.S. consumer demand remained subdued, international leisure bookings grew 13%, and CEO Ariane Gorin noted a recent uptick in American travel sentiment. Expedia raised its full-year booking growth forecast to 3–5%, with margins expected to improve by another 100 basis points. The stock’s pre-market spike to $216 signals sustained investor confidence.

Ad

Expedia Stock: Buy or Sell?! New Expedia Analysis from February 8 delivers the answer:

The latest Expedia figures speak for themselves: Urgent action needed for Expedia investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Expedia: Buy or sell? Read more here...

Tags: Expedia
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Münchener Rück Stock

Münchener Rück Stock: Record Profit Masked by Market Jitters

Gilead Sciences Stock

Gilead Sciences Stock: HIV Success Fuels Analyst Optimism

The Trade Desk Stock

The Trade Desk Stock: Plunges 32% on Downgrade, Growth Fears

Recommended

Lockheed Stock

Lockheed Martin Secures Landmark $9.8 Billion Missile Defense Contract

5 months ago
Ethereum Stock

Ethereum’s Institutional Embrace Gains Momentum

2 months ago
Bionxt Solutions Stock

BioNxt Shares Unmoved by Key Eurasian Patent Approval

3 months ago
Civitas Resources Stock

A New Energy Giant Emerges: SM Energy Completes Major Acquisition

6 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

SuRo Capital Sharpens Focus on AI Infrastructure Investments

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Trending

Berry Petroleum Stock
Analysis

California Resources Navigates Post-Merger Integration and Regulatory Landscape

by Jackson Burston
February 8, 2026
0

With its merger with Berry Petroleum now finalized, California Resources Corporation (CRC) has entered a critical execution...

KemPharm Stock

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

February 8, 2026
Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • California Resources Navigates Post-Merger Integration and Regulatory Landscape
  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com